{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:52Z","timestamp":1788174592384,"version":"build-2803163510"},"reference-count":26,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acalabrutinib is a covalent Bruton tyrosine kinase inhibitor. In the phase 2 ACE-WM-001 trial, at 27.4-month median follow-up, acalabrutinib yielded durable responses in patients with treatment-naive (TN) or relapsed\/refractory (R\/R) Waldenstr\u00f6m macroglobulinemia (WM). We report WM-001 results at 63.7-month median follow-up. Overall, 106 patients (TN, n = 14; R\/R, n = 92) were treated; 52.8% discontinued treatment (TN, n = 7; R\/R, n = 49), most commonly because of disease progression (19.8%; TN, n = 1; R\/R, n = 20) and adverse events (AEs; 17.9%; TN, n = 4; R\/R, n = 15). Overall response rates were 92.9% and 94.6%, and major response rates (partial response or better) were 78.6% and 81.5% in the TN and R\/R cohorts, respectively. Median progression-free survival (PFS) was not estimable (NE; 95% confidence interval, 19.3 to NE) and 67.5 months (53.3 to NE), with estimated 66-month PFS rates of 83.6% (48.0-95.7) and 52.0% (39.3-63.2) in the TN and R\/R cohorts, respectively. Median duration of response (DOR) was not reached (NR) (11.9 months to NE) and 64.7 months (54.5 to NE), with estimated 66-month DOR rates of 90.0% (47.3-98.5) and 44.8% (27.1-61.1) in the TN and R\/R cohorts, respectively. Median overall survival (OS) was NR in both cohorts; estimated 66-month OS rates were 90.9% (50.8-98.7) and 71.2% (60.3-79.6), respectively. Cardiac events of clinical interest occurred in 22 (20.8%) patients. One grade 5 AE (intracranial hematoma) was considered treatment related. With 5 years of follow-up, the efficacy and safety of acalabrutinib in WM were maintained. This trial was registered at www.clinicaltrials.gov as NCT02180724.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017713","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:52Z","timestamp":1776276412000},"page":"5058-5069","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Acalabrutinib in Waldenstr\u00f6m macroglobulinemia yields durable responses with 5 years of follow-up"],"prefix":"10.1182","volume":"10","author":[{"given":"Roger G.","family":"Owen","sequence":"first","affiliation":[{"name":"1Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McCarthy","sequence":"additional","affiliation":[{"name":"2Royal Bournemouth Hospital, Bournemouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-3499","authenticated-orcid":false,"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[{"name":"3University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8596-7058","authenticated-orcid":false,"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[{"name":"4MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"5Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Estaing, EA7453 CHELTER and CIC-1405, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-1831","authenticated-orcid":false,"given":"Francesco","family":"Forconi","sequence":"additional","affiliation":[{"name":"6Cancer Care and Cancer Sciences, Faculty of Medicine, University of Southampton Hospital Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"7Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"8IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, Bologna, Italy"},{"name":"9Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-4160","authenticated-orcid":false,"given":"Sunil","family":"Iyengar","sequence":"additional","affiliation":[{"name":"10Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[{"name":"11Churchill Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"12Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"13Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"14Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet S.","family":"Walter","sequence":"additional","affiliation":[{"name":"15Ernest and Helen Scott Haematological Research Institute and Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0401-2636","authenticated-orcid":false,"given":"Daniel","family":"Greenwald","sequence":"additional","affiliation":[{"name":"16University of California, Los Angeles, Santa Barbara Cancer Center, Santa Barbara, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Calvo","sequence":"additional","affiliation":[{"name":"17AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"18AstraZeneca, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"19AstraZeneca, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"20Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"10","key":"2026072809370742000_bib1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m's macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026072809370742000_bib2","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026072809370742000_bib3","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"25","key":"2026072809370742000_bib4","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"33","key":"2026072809370742000_bib5","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026072809370742000_bib6","author":"Imbruvica","year":"2023"},{"issue":"15","key":"2026072809370742000_bib7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"27","key":"2026072809370742000_bib8","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026072809370742000_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026072809370742000_bib10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"key":"2026072809370742000_bib11","author":"Brukinsa","year":"2025"},{"issue":"suppl 1","key":"2026072809370742000_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2025-226","article-title":"Pirtobrutinib in relapsed\/refractory (R\/R) Waldenstr\u00f6m macroglobulinemia (WM): up to 5 years of follow-up from the phase 1\/2 BRUIN study [abstract]","volume":"146","author":"Cheah","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072809370742000_bib13","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2024-198297","article-title":"A phase II study of pirtobrutinib and venetoclax in previously treated patients with Waldenstr\u00f6m macroglobulinemia: an interim analysis [abstract]","volume":"144","author":"Castillo","year":"2024","journal-title":"Blood"},{"key":"2026072809370742000_bib14","author":"Calquence","year":"2022"},{"issue":"31","key":"2026072809370742000_bib15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026072809370742000_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2026072809370742000_bib17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3816\/CLM.2006.n.013","article-title":"Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's macroglobulinemia","volume":"6","author":"Kimby","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"2026072809370742000_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"21","key":"2026072809370742000_bib19","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-agent ibrutinib for rituximab-refractory Waldenstr\u00f6m macroglobulinemia: final analysis of the substudy of the phase III innovate(TM) trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026072809370742000_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026072809370742000_bib21","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026072809370742000_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"2026072809370742000_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstr\u00f6m macroglobulinaemia: practice patterns, toxicities and outcomes","volume":"188","author":"Abeykoon","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2026072809370742000_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"issue":"7","key":"2026072809370742000_bib25","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","article-title":"Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr\u00f6m macroglobulinemia","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026072809370742000_bib26","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/blood-2024-203317","article-title":"Indolent lymphoma: well tolerated, fixed duration treatment involving bendamustine, rituximab and acalabrutinib for front-line Waldenstr\u00f6m's macroglobulinaemia that induce deep clinical responses [abstract]","volume":"144","author":"Suleman","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/5058\/2534297\/blooda_adv-2025-017713-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/5058\/2534297\/blooda_adv-2025-017713-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:37:14Z","timestamp":1785245834000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/5058\/567773\/Acalabrutinib-in-Waldenstrom-macroglobulinemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017713","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,17]]}}}